Table 3.
Effect of moxifloxacin (not placebo-corrected) on ECG intervals and wave morphology and outlier analysis
| Japanese | Caucasians | |
|---|---|---|
| Mean (SD) change from baseline in time-averaged | ||
| PR interval duration (ms) | − 2.7 (3.5) | − 1.0 (3.3) |
| 90% CI | −3.7, −1.8 | −1.9, −0.2 |
| QRS interval duration (ms) | − 0.4 (1.5) | 0.0 (1.3) |
| 90% CI | −0.8, 0.0 | −0.4, 0.3 |
| QTcF interval (ms) | 3.0 (3.0) | 4.6 (4.7) |
| 90% CI | 2.2, 3.8 | 3.3, 5.9 |
| Outliers | ||
| Significant morphological changes (n and %) | 0 | 0 |
| Bradycardia (n and %) | 0 | 0 |
| Tachycardia (n and %) | 0 | 0 |
| PR interval increased (n and %) | 0 | 0 |
| QRS interval increased (n and %) | 0 | 0 |
| QTcI or QTcF interval increased (n and %) | ||
| >450 ms | 1 (2.5) | 2 (5.0) |
| >480 ms | 0 | 0 |
| >500 ms | 0 | 0 |
| ΔQTcI or ΔQTcF from baseline (n and %) | ||
| >30–60 ms | 0 | 1 (2.5) |
| >60 ms | 0 | 0 |